What's in ClinAmygate's pipeline?

ClinAmygate has 8 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ClinAmygate's portfolio?

Top competitors by shared drug class: Bristol-Myers Squibb, F. Johannes Plate, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/clinamygate.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

ClinAmygate — Portfolio Competitive Intelligence Brief

ClinAmygate pipeline: 8 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Hyaluronan binding system	Hyaluronan binding system	marketed	Drug delivery system / Biopolymer conjugate	Hyaluronan receptors (e.g., CD44)
Early-Corticosteroids	Early-Corticosteroids	marketed
Early-Dexamethasone	Early-Dexamethasone	marketed
Growth Hormones Somatropin Recombinant	Growth Hormones Somatropin Recombinant	marketed	Growth hormone (recombinant human growth hormone)	Growth hormone receptor (GHR)	Endocrinology
Coated Vicryl plus	Coated Vicryl plus	marketed	Absorbable surgical suture with antimicrobial coating		Surgery/Wound Care
Synthetic Vitamin B1	Synthetic Vitamin B1	marketed	Vitamin B1 (thiamine) supplement	Thiamine pyrophosphokinase (enzyme target for activation); functions as cofactor for multiple metabolic enzymes	Nutritional/Metabolic; Neurology
Antagonist	Antagonist	marketed			Other
Late dexamethazone	Late dexamethazone	marketed	Glucocorticoid	Glucocorticoid receptor (GR)	Immunology, Inflammation

Therapeutic area mix

Endocrinology · 1
Immunology, Inflammation · 1
Nutritional/Metabolic; Neurology · 1
Other · 1
Surgery/Wound Care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bristol-Myers Squibb · 1 shared drug class
F. Johannes Plate · 1 shared drug class
First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
First Affiliated Hospital of Zhejiang University · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
Guangzhou JOYO Pharma Co., Ltd · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ClinAmygate:

Cite this brief

Drug Landscape (2026). ClinAmygate — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clinamygate. Accessed 2026-05-13.